On October 20, Eli Lilly rose 5% in Regular Trading, reached an all-time high. The move followed a fresh analyst note indicating Eli Lilly's oral GLP-1 drug Foundayo is expected to keep gaining market share over the next 12 months, alongside a price-target increase to $1397 from $1341 while maintaining a Buy rating.
According to the note, Foundayo already represents 27% of oral GLP-1 new starts in a physician obesity survey and could reach 40% share by 2028 and 2029. The same survey suggested a potentially better Zepbound mix that could keep blended US prices at $480 to $520 in the third and fourth quarters, implying possible upside to near-term expectations. This added to recent momentum after Foundayo received a positive EU recommendation for weight management and type 2 diabetes, expanding the drug's regulatory runway.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
